Viatris VTRS
NASDAQ VTRS
$16.17 -0.07 (-0.43%)
At close: Aug 20, 2026 · 10:04 AM UTC

Viatris (VTRS) Net Income towards Common Stockholders (2019 - 2026)

Viatris (VTRS) posted quarterly Net Income towards Common Stockholders of $176.4 million for Q1 2026, up 105.8% year-over-year from $85.7 million in Q1 2025, and up 151.87% quarter-over-quarter from -$340.1 million in Q4 2025.

Viatris (VTRS) Net Income towards Common Stockholders (2019 - 2026) Analysis & Trends

Viatris' Net Income towards Common Stockholders history runs 8 years deep, the most recent figure standing at $176.4 million for Q1 2026.

  • In Q1 2026, Net Income towards Common Stockholders rose 105.8% year-over-year to $176.4 million; the TTM figure through Mar 2026 stood at -$296.5 million (up 92.18% YoY), while the FY2025 annual figure was -$3.5 billion, down 454.23% from the prior year.
  • Net Income towards Common Stockholders for Q1 2026 stood at $176.4 million, up from -$340.1 million in the prior quarter.
  • The five-year high for Net Income towards Common Stockholders was $1.0 billion in Q4 2022, with the low at -$3.0 billion in Q1 2025.
  • The 5-year median for Net Income towards Common Stockholders is $113.9 million (2024), against an average of -$108.2 million.
  • The sharpest annual moves came in 2022 and 2025: Net Income towards Common Stockholders soared 483.32% in 2022, then sank 2770.76% in 2025.
  • Viatris' Net Income towards Common Stockholders stood at $1.0 billion in 2022, then tumbled by 175.71% to -$765.6 million in 2023, then soared by 32.54% to -$516.5 million in 2024, then soared by 34.15% to -$340.1 million in 2025, then soared by 151.87% to $176.4 million in 2026.
  • Business Quant data shows VTRS's Net Income towards Common Stockholders at $176.4 million in Q1 2026, -$340.1 million in Q4 2025, and -$128.2 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Haleon 43.76 Bn 42.80 Bn - -
2 Teva Pharmaceutical Industries 43.05 Bn 39.39 Bn 2.15 Bn -576.00 Mn
3 Zoetis 31.51 Bn 29.84 Bn 1.05 Bn 866.00 Mn
4 Takeda Pharmaceutical 28.70 Bn 22.90 Bn 5.10 Bn 710.19 Mn
5 United Therapeutics 22.27 Bn 19.61 Bn 683.80 Mn 333.00 Mn
6 Viatris 18.83 Bn 17.95 Bn 1.46 Bn -118.80 Mn
7 Neurocrine Biosciences 15.65 Bn 15.26 Bn 935.80 Mn 144.40 Mn
8 Elanco Animal Health 12.06 Bn 11.53 Bn 798.00 Mn 54.00 Mn
9 Dr Reddys Laboratories 10.12 Bn 9.95 Bn - -
10 Alkermes 8.27 Bn 7.61 Bn 397.90 Mn 524,000.00

Historic Data

Download Data
DateValue
Jun 30, 2026 -118.80 Mn
Mar 31, 2026 176.40 Mn
Dec 31, 2025 -340.10 Mn
Sep 30, 2025 -128.20 Mn
Jun 30, 2025 -4.60 Mn
Mar 31, 2025 -3.04 Bn
Dec 31, 2024 -516.50 Mn
Sep 30, 2024 94.80 Mn
Jun 30, 2024 -326.40 Mn
Mar 31, 2024 113.90 Mn
Dec 31, 2023 -765.60 Mn
Sep 30, 2023 331.60 Mn
Jun 30, 2023 264.00 Mn
Mar 31, 2023 224.70 Mn
Dec 31, 2022 1.01 Bn
Sep 30, 2022 354.30 Mn
Jun 30, 2022 313.90 Mn
Mar 31, 2022 399.20 Mn
Dec 31, 2021 -263.80 Mn
Sep 30, 2021 311.50 Mn